Topics

New migraine drug not cost-effective NICE says in draft guidance

19:01 EST 9 Jan 2019 | Drug Discovery Today

NICE has today (10 January) published draft guidance for public consultation which does not recommend erenumab (Aimovig, Novartis) for preventing migraine.

Original Article: New migraine drug not cost-effective NICE says in draft guidance

NEXT ARTICLE

More From BioPortfolio on "New migraine drug not cost-effective NICE says in draft guidance"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...